Punchgrafting Techniques for Vitiligo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale: Punch grafting is a safe, simple and widely used technique for in vitiligo. However, no reliable data are available on the effect of punch depth and punch size.

Objectives: Primary: to compare the efficacy and safety of different punchdepths and punchsizes in punch grafting in patients with segmental and non-segmental vitiligo. Secondary: to assess the practical aspects and patients preference of different punch grafting techniques.

Study design: Prospective observer blinded randomised controlled study. Study population: 35 patients ≥ 18 years with segmental or stable non-segmental vitiligo who will receive regular treatment by punch grafting at the Netherlands Institute for Pigment Disorders (SNIP) at the Academic Medical Centre University of Amsterdam.

Methods: Four depigmented regions on the trunk or upper extremities will be randomly allocated to either epidermal 1,5 mm punch grafting, epidermal 1mm punch grafting, dermal 1,5 mm punch grafting and dermal 1 mm punch grafting. After grafting, all regions will receive UV-therapy twice a week for 3 months. Three and six months after grafting, the repigmentation of the lesions will be assessed by measuring the outgrowth.

Main study parameter/endpoint: Outgrowth of pigment after six months.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The study involves 16 additional punch grafts but no additional visits to our institute. Patients will not miss any regular treatment. The extra time due to participation in the study will be about 40 minutes. No increase of the risk of side effects is expected by placing 16 additional punch grafts. 1.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

NCT01640678

Piebaldism Segmental Vitiligo

UNKNOWN PHASE4

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

NCT02458417

Segmental Vitiligo Piebaldism

COMPLETED PHASE4

Autologous Cellular Graft in Surgical Treatment of Vitiligo

NCT05503368

Vitiligo, Generalized

SUSPENDED NA

Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo

NCT04374435

Vitiligo

TERMINATED NA

Effect of Procedural Variables on Outcome of Surgical Treatment of Vitiligo

NCT02510651

Vitiligo

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-segmental Vitiligo Segmental Vitiligo Piebaldism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

punchgrafting

autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions

Intervention Type PROCEDURE

punchgrafting

autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non-segmental and segmental vitiligo under medical treatment at the Netherlands Institute for Pigment Disorders
* Age between 18 and 60 years
* Patient is willing and able to give written informed consent
* Vitiligo stable since 12 months without systemic therapy or 6 months without topical therapy as defined by the absence of new lesions and/or enlargement of existing lesions.
* Vitiligo lesions on the extremities or trunk larger than 5x5cm

Exclusion Criteria

* UV therapy or systemic immunosuppressive treatment during the last 12 months
* Local treatment of vitiligo during the last 6 months
* Vitiligo lesions with folliculair or non-folliculair repigmentations
* Skin type 1
* Hypertrophic scars
* Keloid
* Cardial insufficiency
* Patients with a history of hypersensitivity to (UVB) light and allergy to local anesthesia.
* Patients who are pregnant or breast-feeding
* Patients not competent to understand what the procedures involved
* Patients with a personal history of melanoma or non-melanoma skin cancer
* Patients with a first degree relative with melanoma skin cancer
* Patients with atypical nevi.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No